Lōkahi Therapeutics™ Expands ai2 Pipeline™ Program Through Collaboration with Pepperdine E2B™

Lōkahi Therapeutics™ Expands ai(2) Pipeline™ Program Through Collaboration with Pepperdine E2B™

Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced that it will partner with Pepperdine E2B™ (Education to Business) to engage students in its ai(2) Pipeline™ initiative during the upcoming academic year. The collaboration is intended to provide students with hands-on experience evaluating real-world biopharmaceutical opportunities while supporting Lōkahi's ongoing efforts to identify and assess therapeutic assets through its ai(2) platform.